Imipenem / Cilastatin Eberth

Powder for solution for infusion

Imipenem / Cilastatin Eberth


dosage form

pack size


pharmaceutical registration number


500 mg

powder for solution for infusion

10 vials



Active substance:
Imipenem + Cilastatin

Pharmacotherapeutic group:
Antibacterials for systemic use, carbapenems
ATC code: J01DH51

Mechansim of action:
Imipenem / Cilastatin Eberth consists of two components: imipenem and cilastatin sodium in a 1:1 ratio by weight.

Imipenem, also referred to as N-formimidoyl-thienamycin, is a semi-synthetic derivative of thienamycin, the parent compound produced by the filamentous bacterium Streptomyces cattleya.

Imipenem exerts its bactericidal activity by inhibiting bacterial cell wall synthesis in Gram-positive and Gram-negative bacteria through binding to penicillin-binding proteins (PBPs).

Cilastatin sodium is a competitive, reversible and specific inhibitor of dehydropeptidase-I, the renal enzyme which metabolizes and inactivates imipenem. It is devoid of intrinsic antibacterial activity and does not affect the antibacterial activity of imipenem.

Therapeutic indications:
Imipenem / Cilastatin Eberth is indicated for the treatment of the following infections in adults and children 1 year of age and above:

  • complicated intra-abdominal infections
  • severe pneumonia including hospital and ventilator-associated pneumonia
  • intra- and post-partum infections 
  • complicated urinary tract infections
  • complicated skin and soft-tissue infections

Imipenem / Cilastatin Eberth may be used in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection.

Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.